The role of porfimer sodium (Photofrin™) in the ablation of high-grade dysplasia associated with Barrett’s esophag

Brief Summary

GUIDELINE TITLE

The role of porfimer sodium (Photofrin™) in the ablation of high-grade dysplasia associated with Barrett’s esophagus.

BIBLIOGRAPHIC SOURCE(S)

Malthaner RA, Rumble RB, Program in Evidence-based Care. The role of porfimer sodium (photofrin) in the ablation of high-grade dysplasia associated with Barrett's esophagus. Toronto (ON): Cancer Care Ontario (CCO); 2006 Jun 14. 14 p. (DQTC-SOS advice report; no. 2). [12 references]

GUIDELINE STATUS

This is the current release of the guideline.

Please visit the Cancer Care Ontario Web site for details on any new evidence that has emerged and implications to the guidelines.

BRIEF SUMMARY CONTENT

RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

For patients with high-grade dysplasia associated with Barrett's esophagus and who are willing and able to tolerate surgery, surgery alone should be the first treatment of choice.
For patients with high-grade dysplasia associated with Barrett's esophagus with contraindications to surgery, or who choose not to receive surgery, there are randomized controlled trial data confirming that photodynamic therapy (PDT) with porfimer sodium followed by laser light shows superiority over omeprazole alone in the ablation of high-grade dysplasia. Therefore, photodynamic therapy with porfimer sodium could be considered a treatment option for these patients.

See Appendix 1 in the original guideline document for recommended regimens and dosages, and Appendix 2 in the original guideline for the regimens and dosages used in the included trials.

CLINICAL ALGORITHM(S)

None provided

Top^

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The recommendations are supported by one randomized controlled trial (RCT), three prospective case-series, one retrospective, and one post-treatment patient satisfaction survey.

Top^

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Malthaner RA, Rumble RB, Program in Evidence-based Care. The role of porfimer sodium (photofrin) in the ablation of high-grade dysplasia associated with Barrett's esophagus. Toronto (ON): Cancer Care Ontario (CCO); 2006 Jun 14. 14 p. (DQTC-SOS advice report; no. 2). [12 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2006 Jun 14

GUIDELINE DEVELOPER(S)

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]

GUIDELINE DEVELOPER COMMENT

The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

SOURCE(S) OF FUNDING

Cancer Care Ontario
Ontario Ministry of Health and Long-Term Care

GUIDELINE COMMITTEE

Cancer Care Ontario's Program in Evidence-Based Care

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Authors: R.A. Malthaner; R.B. Rumble

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Neither of the authors declared any conflicts of interest.

GUIDELINE STATUS

This is the current release of the guideline.

Please visit the Cancer Care Ontario Web site for details on any new evidence that has emerged and implications to the guidelines.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the Cancer Care Ontario Web site.

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

The role of porfimer sodium (Photofrin™) in the ablation of high-grade dysplasia associated with Barrett's esophagus. Summary. Toronto (ON): Cancer Care Ontario (CCO), 2006 Jun 14. Various p. Electronic copies: Available in Portable Document Format (PDF) from the Cancer Care Ontario Web site.
Browman GP, Levine MN, Mohide EA, Hayward RSA, Pritchard KI, Gafni A, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13(2):502-12.

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on October 26, 2006. The information was verified by the guideline developer on November 24, 2006.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please refer to the Copyright and Disclaimer Statements posted at the Program in Evidence-Based Care section of the Cancer Care Ontario Web site.

Top^

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

Top^

Brief Summary

GUIDELINE TITLE

BIBLIOGRAPHIC SOURCE(S)

GUIDELINE STATUS

BRIEF SUMMARY CONTENT

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

CLINICAL ALGORITHM(S)

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

ADAPTATION

DATE RELEASED

GUIDELINE DEVELOPER(S)

GUIDELINE DEVELOPER COMMENT

SOURCE(S) OF FUNDING

GUIDELINE COMMITTEE

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

GUIDELINE STATUS

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

NGC STATUS

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

Search

Summary

Browse

Compare